跳至主要内容
临床试验/NCT04123938
NCT04123938已完成不适用

A Pilot Study to Examine the Effect of Pea Protein on Limiting the Loss of Muscle Mass During Weight Loss

University of Manitoba2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年10月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Change in muscle mass

研究概览

简要总结

A pilot study comparing the effects of pea protein versus whey protein on the preservation of muscle mass and functionality in individuals undertaking a weight loss regimen.

详细描述

A single site, double-blind, randomized clinical trial designed to compare the effects of pea protein or whey protein or maltodextrin supplementation on muscle mass and functionality in males and females with obesity undertaking a weight loss regimen. Eligible participants will be randomized to one of the three groups (pea protein, whey protein, maltodextrin) and will be asked to attend 3 in-person clinic visits (0, 6, and 12 weeks) for blood and urine collection and assessments of muscle mass and muscle function. A separate visit for screening and for a fasting blood sample, as well as a Pre-Study visit and a meeting with a registered dietitian, will be required.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
30 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male, or non-pregnant, non-lactating female, 30 to 50 years of age;
  • BMI >30 and body weight does not exceed the capacity of the DEXA (350 lbs);
  • Fat mass >23% for males and >32% for females (determined at the screening visit via bioelectrical impedance);
  • Willing to maintain a stable level of activity while participating in the study;
  • Plasma creatinine ≤265 µmol/L;
  • Plasma LDL-cholesterol <5 mmol/L;
  • Aspartate aminotransferase <160 U/L, and alanine aminotransferase <150 U/L;
  • Glycated hemoglobin <6.5%;
  • Blood pressure <160 mmHg systolic and <100 mmHg diastolic;
  • Stable regime if taking vitamin and mineral/dietary/herbal supplements for the past 1 month and while participating in the study;
  • Not taking protein supplements for the past month and willing to continue doing so for the duration of the study;
  • Has not donated blood or blood products (e.g. platelets) during the past 2 months and willing to continue doing so while participating in the study;
  • Female participants of child-bearing potential must agree to use a highly effective method of contraception throughout the study;
  • Not participating in another dietary intervention trial for the past month and willing to not start another dietary intervention trial or weight loss program for the duration of this study;
  • Willing to comply with the protocol requirements and procedures;
  • Willing to provide informed consent.

排除标准

  • Has experienced a cardiovascular event (e.g. heart attack, stroke) or had a surgical procedure for cardiovascular disease (e.g. bypass, stent), presence of diabetes, chronic renal disease, liver disease (with exception of fatty liver), rheumatoid arthritis, immune disorder or disease (e.g. multiple sclerosis, leukemia), cancer in the previous 5 years, neurological disorders, gastrointestinal disorders or gastrointestinal surgery or bariatric surgery, or liposuction;
  • Taking medications for blood glucose management;
  • Taking medications or natural health products/supplements associated with weight gain or weight loss (e.g. prednisone, certain cold medications);
  • Body weight that has not been stable (± 5%) over the past 3 months;
  • History of gastrointestinal reactions or allergies to peas, pea protein, whey protein or maltodextrin, or to one or more ingredients in the beverages and foods that will be provided which significantly limits the number of items that can be used for delivery of the protein powders or maltodextrin;
  • Current (within the past 30 days) bacterial, viral or fungal infection;
  • Uncontrolled hypothyroidism;
  • Uncontrolled blood pressure;
  • Bleeding disorder;
  • Any acute medical condition or surgical intervention within the past 3 months;
  • Cigarette/cigar smoking or use of tobacco products within the last 12 months or during participation in the study;
  • Consumption of >10 alcoholic beverages per week or >2 alcoholic beverages per day within the last 3 months or while participating in the study;
  • Drug and/or alcohol abuse;
  • Psychological disorder(s);
  • Unable to obtain blood sample at the screening or week 0 visits.

结局指标

主要结局

Change in muscle mass

时间窗: Baseline and 12 weeks

Muscle mass will be assessed by dual x-ray absorptiometry

Change in muscle function (hand grip)

时间窗: Baseline and 12 weeks

A dynamometer will be used to measure hand grip strength

Change in muscle function (gait test)

时间窗: Baseline and 12 weeks

A gait test will be performed

次要结局

  • Change in C-reactive protein(Baseline and 12 weeks)
  • Change in liver function (based on profile of circulating markers)(Baseline and 12 weeks)
  • Change in kidney function (based on profile of urinary markers)(Baseline and 12 weeks)
  • Changes in blood vessel function(Baseline and 12 weeks)
  • Change in kidney function (based on profile of circulating markers)(Baseline and 12 weeks)
  • Change in systolic and diastolic blood pressure(Baseline and 12 weeks)
  • 24 h activity patterns over time(Up to 12 weeks)
  • Change in fat mass(Baseline and 12 weeks)
  • Change in waist and waist to height ratio(Baseline and 12 weeks)
  • Change in homeostatic model for insulin resistance (HOMA-IR)(Baseline and 12 weeks)
  • Food intake over time(Up to 12 weeks)
  • Change in body weight and body mass index(Baseline and 12 weeks)
  • Change in resting energy expenditure(Baseline and 12 weeks)
  • Change in glycated hemoglobin(Baseline and 12 weeks)
  • Change in blood lipid profile(Baseline and 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Peter Zahradka

Principal Investigator

University of Manitoba

研究点 (2)

Loading locations...

相似试验